Pharmacological analysis of metabolic syndrome appraised by oxidative stress markers
Metabolic syndrome (MS) is recognized as a clinical-pathological entity, where central obesity and insulin resistance/compensatory hyperinsulinemia are the pathophysiological triggers of this disease. It has been determined that in MS a state of low-grade systemic inflammation is generated. It...
Guardado en:
| Autores principales: | Castillo, TA, Scribano Parada, MP, Tarán, M, Balceda, A, Rossi, MM, Blencio, S, Moya, M, Baez, MC |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2019
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/25704 |
| Aporte de: |
Ejemplares similares
-
New therapeutic approach in fatty liver disease associated with metabolic dysfunction
por: Castillo, TA, et al.
Publicado: (2021) -
Estudio comparativo entre atorvastatina y metformina sobre la actividad mitocondrial del complejo III hepático en síndrome metabólico experimental
por: Castillo, TA, et al.
Publicado: (2018) -
In vitro effects from atorvastatin and metformin on cell proliferation induced by dyslipidemic contexts in benign prostatic hyperplasia
por: Reinarz Torrado, KF, et al.
Publicado: (2022) -
Aortic morphological changes in Metabolic Syndrome: Therapeutic contrast with atorvastatin and sleeve gastrectomy
por: Rossi, MM, et al.
Publicado: (2022) -
La combinación de metformina y naringina revierte la inflamación hepática inducida por el síndrome metabólico experimental
por: inflammation, ID, et al.
Publicado: (2025)